Latest news with #Intuitive
India.com
18 hours ago
- Health
- India.com
Why Tech Must Prioritize Surgeon-Centric Design in 3D Surgical Platforms by Arjun Urs
Medicine and technology evolution of novel freedoms ushering in a disruption in surgical design and patient disposition is therefore believed to be an emancipatory force. This 3D surgical platform provides the surgeon with a detailed view of body structures relevant to the patient and surgical techniques performed with an appropriate degree of precision. There exist such digital or computerized tools that do not stand with real surgical decision-makers, i.e., the operating surgeons. Hence the operating platform technology for these complex and urgent surgeries must now change the philosophy on which it has been designed from being an engineering-centrist one to being a surgeon-need-centric one. It should now set surgical teams' needs, their cognitive workflows, and their feedback methods with utmost precedence, as these are clinically imperative and cannot be compromised. Ill-designed systems would obstruct smooth conduct of operations and thereby endanger clinical success, while well-designed platforms promote cooperation and rapid clinical decision-making towards superior healthcare delivery. Arjun Urs: Engineering Empathy into High Stakes Technology This gap between technology and surgical practice is what Arjun Urs makes it his perennial assignment to build over. From within, he is considered to be the founding engineer of Intuitive, and, also as architecting the 3D Models Platform, Urs transformed the way surgical teams interfaced with digital planning tools. Accordingly, immersing oneself in the perspective of the end-user rather than formally assessing a product in terms of functionality, Urs shadowed surgeons through their workflows and translated real-world frustrations into design features that actually matter. Currently, hospital staff and surgeons use this cloud-based system to effortlessly order and visualize those 3D anatomical models: the genuine patient-specific models. Some of the features implemented under Urs' direction include the aforesaid context-aware annotations, one-click ordering, and web/mobile interfaces. These functions are inherently tied to improvements in usability: with pre-op planning time cut down, internal requests for support visibly fell; and within a year's time, the platform was operating in hundreds of departments. From Prototype to Platform: Architecting for Clinical Impact He calmed the mind of his inner philosopher, distilled the very surgeon-centric conceptual ethos through his efforts into a HIPAA-compliant, multi-departments system. He integrated clinical metadata into the ordering workflow and in that capacity enhanced the usability of the system further by integrating it with AWS serverless infrastructure, thereby striving for a state of technical excellence. This created an extremely interactive platform for collaborative work which significantly improved model management coupled with instant access to CT, MRI, and segmentation data on desktops, tablets, and mobiles. A rather rare integration of strict backend engineering with front-end empathy was the driving force behind the great adoption and huge impact of the platform. Beyond this, Urs enhanced the UX, which stripped away the bulk of cognitive load, drastically cut down switch time between tools, and re-engineered the 3D model revision workflow to reduce average turn-around time from days to less than one. More importantly, surgeons reported feeling much more confident about proceeding with clarity and smoothly guided workflows when performing these complex cases. Solving Problems Others Didn't Know Existed Much of his success pivots on working on gaps that were always falling through the cracks. By means of WebGL and progressive model loading, he innovated and optimized low-power device accessibility so that even under-resourced hospitals could utilize this advanced visualization tool. He approached problems from the angle of bridging the communication gap between engineers and clinicians by facilitating multidisciplinary sessions that converted clinical dissatisfactions into improvements in design that could be acted upon. The recognition for the results can be seen in the greater platform adoption and rise in ever-increasing rate of successful completions of order. Looking Forward: Integration, Not Just Innovation He holds the view that the future of 3D surgical platforms is not merely about richer visuals but rather integration. 'The real innovation lies in enabling non-linear surgical thinking,' he says. 'Surgeons don't operate in a straight line from diagnosis to decision. They loop back, consult, annotate, and pivot. Bringing us into an era in which hospitals are set to digitize and personalize surgical care, the approach by Arjun Urs stands as a brilliant testament to what happens when the frontier of engineering meets empathetic design. Surgeon-centric technology basically translates to better clinical outcomes besides being a better user experience.
Yahoo
30-07-2025
- Business
- Yahoo
One Buy-Rated Stock With an Unbreakable Moat That You Can't Ignore
Intuitive Surgical (ISRG), valued at $177 billion, is a medical technology company best known for its da Vinci Surgical System. It has long held a monopoly on the robotic surgery market with the da Vinci systems, a robotic platform that helps surgeons perform minimally invasive surgeries. Its success is based on a two-decade-old ecosystem of surgeon loyalty, hospital dependency, and technological supremacy. During the same period, the stock returned more than 6,330%. With advancements in artificial intelligence (AI), Intuitive can now further develop its system, solidifying its unbreakable moat. Let us see if the stock is currently a buy. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! A Unique and Strong Business Model Intuitive's da Vinci system is an advanced robotic system that allows surgeons to operate through small incisions using robotic arms and a 3D high-definition camera, giving them greater precision, control, and vision. These minimally invasive surgeries result in fewer complications, shorter hospital stays, and faster recovery times. Intuitive's business model includes not only selling these systems but also earning recurring revenue from sales of system-related instruments and accessories, as well as surgeon training programs. In the most recent second quarter, global da Vinci procedures increased 17% year over year. The company installed 395 da Vinci systems in Q2, including 180 da Vinci 5 systems, its fifth-generation robotic system, which the company launched in 2024. Total revenue increased by 21% to $2.44 billion, with adjusted earnings up 23% to $2.19 per share. Despite an increase in the average selling price (ASP) of da Vinci systems from $1.44 million to $1.5 million, systems revenue increased by 28% due to increased placements and demand for the company's latest da Vinci platforms. This reveals that hospitals are prioritizing investments in Intuitive's cutting-edge surgical platforms, despite broader capital expenditure constraints in some global markets. Additionally, instruments and accessories revenue also rose by 18% YoY to $1.47 billion. One standout performer in the quarter was the SP (Single Port) platform, which grew procedures by 88% year on year. It is used in confined anatomical spaces and complex cases such as colorectal or head and neck surgeries, where traditional multiport robotic systems may fail to function. In the second quarter, Intuitive placed 23 SP systems. Additionally, the Ion system, Intuitive's robotic-assisted platform for minimally invasive lung biopsies, saw a 52% increase in procedures to 35,000, with an installed base of 905 systems. Despite macroeconomic uncertainty and rising trade tensions, gross margins remained at 67.9%. The company repurchased $181 million worth of shares and spent $155 million in capex, yet grew its cash reserves to $9.5 billion. Looking ahead, the company intends to launch da Vinci 5 globally. Intuitive is well-positioned to execute, with a healthy balance sheet, recurring revenue model, and strong free cash flow. The Unbreakable Moat Intuitive has a two-decade headstart in the field of robotic surgery. According to GlobalData, Intuitive held 60% of the global robotic surgery market in 2024. This market, which was valued at $2.9 billion in 2024, is expected to reach $9.2 billion by 2034. Intuitive has installed over 11,000 da Vinci systems across 74 countries. Bringing a robotic system to market requires years of research and development, surgeon partnerships, billions of dollars, and regulatory hurdles. Even if a new entrant or an established player attempts to enter this space, they must show clinical efficacy, safety, and training scalability at a level that matches Intuitive. Rivals with deep pockets have developed alternatives. Notably, Medtronic (MDT) with its Hugo system, Johnson & Johnson (JNJ) with its Ottava surgical system, and Stryker (SYK) with its Mako system have all attempted but failed to gain market share. This is due in part to hospitals and surgeons being locked into the da Vinci ecosystem, where they have invested a significant amount of money to purchase these systems and train their surgeons. Once trained, switching platforms is costly and risky. That's what makes the moat so unbreakable. Besides the da Vinci, Intuitive has expanded its reach into pulmonology, colorectal, thoracic, and head-and-neck surgeries with Ion, SP, and staplers, creating a diversified model. Overall, Intuitive is a growth stock with decades of innovation, operational excellence, and a moat based on technological superiority and clinical outcomes that competitors will find difficult to replicate. Is ISRG Stock a Buy, Hold, or Sell on Wall Street? On Wall Street, overall, Intuitive stock is a 'Moderate Buy.' Out of the 28 analysts that cover the stock, 18 rate it a 'Strong Buy,' two suggest a 'Moderate Buy,' seven rate it a 'Hold,' and one says it is a 'Strong Sell.' The average target price of $602.96 is 21% above current levels. The high price estimate of $675 implies 36% upside over the next 12 months. Despite its unbreakable moat and excellent long-term growth prospects in the robotic surgery market, ISRG stock is currently trading at a premium of 60x forward earnings. Risk-averse investors can start accumulating shares around the $400 level to invest with a margin of safety. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UAE Moments
28-07-2025
- Business
- UAE Moments
♓ Pisces Daily Horoscope for July 28, 2025
Love Your heart is wide open today, Pisces, and the emotional currents run deep. If you're in a relationship, take a moment to do something romantic or meaningful—your partner will notice the effort. Single Pisces may encounter someone through a shared creative or spiritual interest. Let things flow, don't force connection. Career Your ideas are gold—but only if you take action. Daydreaming won't move you forward unless you write those thoughts down and pitch them. Colleagues may be inspired by your gentle leadership today, so don't hold back from sharing your thoughts during meetings. Finance Today is ideal for envisioning your financial goals and creating a plan to reach them. It's not about big gains right now—it's about quiet consistency. Skip the gamble, trust the plan. Health You might feel more emotionally drained than physically tired. Your nervous system is sensitive today, so lean into calming routines: herbal teas, soft music, and early rest. Pay attention to your dreams tonight—they might reveal something useful. Other Important Note You're extra intuitive today, so if something feels off, trust that instinct.
Yahoo
15-07-2025
- Business
- Yahoo
Medtronic's Hugo robot wins CE mark for vessel-sealing technology
Medtronic has secured EU CE mark approval for LigaSure RAS, a vessel-sealing instrument for use with the company's Hugo robotic-assisted surgery (RAS) system. LigaSure is indicated for sealing and cutting vessels, thick tissue, and lymphatics up to 7mm in diameter and expands Hugo's capabilities in areas such as gynaecologic and urologic procedures. According to Medtronic, LigaSure seals vessels within two seconds and minimises thermal spread to surrounding tissue. Medtronic senior vice-president Matt Anderson said: 'With CE mark for LigaSure RAS, Medtronic is fulfilling a promise to customers to integrate our trusted vessel-sealing technology onto the Hugo RAS system. 'More than fulfilling a commitment, this regulatory approval is a big step forward as we continue to shape the future of surgery.' Hugo has been in use in Europe since 2022 and was recently recommended by the National Institute for Health and Care Excellence (NICE) as one of 11 surgical robots set to be used across the UK National Health Service (NHS). While Hugo is not yet available in the US, Medtronic's submission for a urology indication for the robot is currently under review with the US Food and Drug Administration (FDA), with US market entry expected later this year. In anticipation of Hugo's approval with the FDA, Medtronic is currently building out its training provision for the RAS system following the introduction of live streaming to its Touch Surgery Ecosystem (TSE) last year. The broad aim of Medtronic's surgical training provision is to enhance and democratise surgical education on a global scale, removing barriers to training such as geographic location. With its da Vinci surgical robot, Intuitive Surgical currently holds the largest share of the global robotic surgery market at almost 60%, according to GlobalData analysis. The market is forecast to reach a valuation of $9.2bn by 2034, up from around $2.9bn in 2024. Due to Medtronic's size, the Hugo is expected to pose the main challenge to Intuitive's da Vinci robot once the former is approved in the US. According to GlobalData analyst Grayson Vigneux, due to Intuitive's 20-year head start in the US robotic surgery market, its vast installed base and long-standing reputation, Hugo is 'more likely to capture new customers rather than immediately displace Intuitive's existing market'. "Medtronic's Hugo robot wins CE mark for vessel-sealing technology" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Time Magazine
10-07-2025
- Business
- Time Magazine
America's Best Midsize Companies of 2025
I n the U.S., large companies dominate headlines and industry discussions, but mid-sized companies, which have revenues between $100 million to $10 billion, undergird the economy. To provide a comprehensive view of that economic foundation, TIME and Statista have created the second annual list of the best mid-sized companies in the U.S., ranked by employee satisfaction, revenue growth, and sustainability transparency. The list includes both the core and upper mid-market segments; the upper threshold of $10 billion annual revenue aims to capture the most influential players within this category, along with the emerging leaders. But these are not startups. 'The average age of a mid-sized company in the U.S. is about 34 years,' says Doug Farren, the managing director of the National Center for the Middle Market at The Ohio State University Fisher College of Business. 'They're really at a sweet spot where they have enough years of experience, sustained success, to be able to expand into new markets, introduce new products and services. A lot of them are thinking about ways that they can innovate and grow.' These businesses, based locally and regionally, make up the backbone of many communities, according to Farren, and over 90 percent of mid-size businesses are private. 'Most of these companies tend to be in the supply chains of larger and smaller companies,' Farren says. 'The automotive industry, for example, [has] 3,000 to 5,000 suppliers who just make parts for automotive manufacturing in the U.S., and they're all mid-sized companies themselves.' Technology and life sciences are the two fastest growing industries in the mid-market, echoing a much larger trend of U.S. tech dominance and leadership in drug innovation. In the tech space, Airbnb took the top spot in this year's list, followed by Hubspot, the first customer service platform to integrate ChatGPT. TIME and Statista used 2023 financial data for the list, during which Airbnb had an annual revenue of $9.9 billion, but last December, the company reported a 2024 annual revenue of $11.1 billion, putting it on the precipice of becoming a large-cap company. In its first quarter 2025 letter to shareholders, the company wrote that it's been laying the groundwork for long-term growth and its 'next chapter,' while navigating changing global regulations around short-term rentals. This involves a redesigned Airbnb app that allows users to book services and experiences. Intuitive (no. 13), a leader in surgery robots, is behind the robotic surgical system used in the world's first fully robotic lung transplant at NYU and first robotic heart transplant at Baylor. 'Since the pandemic, we've seen life sciences really take off,' Farren says. 'Things like testing centers, laboratories, not necessarily big pharma, but places that support that industry, [have had] rapid growth.' In May, Intuitive received an extended FDA clearance for colorectal surgery, and its first quarter revenue of $2.25 billion was 19% higher compared to the first quarter of 2024, with much of the growth due to more robotic surgeries. New Balance is the top apparel, footwear, and sporting goods company (at no. 3), thanks to the popularity of comfy 'dad-shoes', and collabs with athletes and buzzy brands like Miu Miu, Loro Piana, and Ganni. In 2024, it reported $7.8 billion in sales, and projects to reach $10 billion in sales in the next few years. The private Boston-based brand launched a 'Made in USA' line in 2024 with 70% of its products hand stitched in domestic factories across Massachusetts and Maine. But despite domestic manufacturing, tariffs are a major concern for many of the midsize U.S. companies on the list. 'Sourcing is a global activity,' says Farren. Which means imposing tariffs in hopes of bringing manufacturing back to the U.S. is 'not that simple…You have to find new suppliers…but it won't be quick, and it won't be cheap.' —Charlotte Hu See the full list below.
